Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

Thumbnail for Real-World Renal Toxicity and Survival Outcomes Following Hematopoietic Stem Cell Transplantation: A Propensity Score-Matched TriNetX Database Analysis of Total Body Irradiation Versus Chemotherapy-Only Conditioning

CT - 1369

Real-World Renal Toxicity and Survival Outcomes Following Hematopoietic Stem Cell Transplantation: A Propensity Score-Matched TriNetX Database Analysis of Total Body Irradiation Versus Chemotherapy-Only Conditioning

Wei Ju Lin

Poster Presenter: Wei Ju Lin

Thumbnail for Real-World Safety and Efficacy of Frontline Nivolumab Combined with Doxorubicin, Vinblastine, and Dacarbazine in Adult Classical Hodgkin Lymphoma

HL - 663

Real-World Safety and Efficacy of Frontline Nivolumab Combined with Doxorubicin, Vinblastine, and Dacarbazine in Adult Classical Hodgkin Lymphoma

Ajay Gogia

Poster Presenter: Ajay Gogia

Thumbnail for Real-World Safety Comparison of BTK Inhibitors in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis of Acalabrutinib, Ibrutinib, and Zanubrutinib

CLL - 1019

Real-World Safety Comparison of BTK Inhibitors in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis of Acalabrutinib, Ibrutinib, and Zanubrutinib

Vishw Patel

Poster Presenter: Vishw Patel

$Thumbnail for Real-World Safety Profile of Ciltacabtagene Autoleucel in Triple-Class Refractory Multiple Myeloma: A TriNetX Analysis.$

MM - 881

Real-World Safety Profile of Ciltacabtagene Autoleucel in Triple-Class Refractory Multiple Myeloma: A TriNetX Analysis.

Hira Cheema

Poster Presenter: Hira Cheema

Thumbnail for Real-World Survival and Safety of Isatuximab-Based vs Daratumumab-Based VRd Exposure in Multiple Myeloma

MM - 1202

Real-World Survival and Safety of Isatuximab-Based vs Daratumumab-Based VRd Exposure in Multiple Myeloma

Xiaoyi Zhang

Poster Presenter: Xiaoyi Zhang

Thumbnail for Real-World Survival Outcomes With Pirtobrutinib vs Bendamustine/Rituximab in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis

CLL - 1140

Real-World Survival Outcomes With Pirtobrutinib vs Bendamustine/Rituximab in Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis

Laraib Jahejo

Poster Presenter: Laraib Jahejo

Thumbnail for Real-World Treatment and Survival Outcomes for Zanubrutinib and Acalabrutinib Monotherapy Among Treatment-Naive Patients With Chronic Lymphocytic Leukemia in the United States

CLL - 160

Real-World Treatment and Survival Outcomes for Zanubrutinib and Acalabrutinib Monotherapy Among Treatment-Naive Patients With Chronic Lymphocytic Leukemia in the United States

Daniel A. Ermann

Poster Presenter: Daniel A. Ermann

Thumbnail for Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib

MPN - 564

Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib

Naveen Pemmaraju

Poster Presenter: Naveen Pemmaraju

Thumbnail for Real-World Treatment Patterns and Outcomes With Olutasidenib After Venetoclax in IDH1-Mutated Acute Myeloid Leukemia Using Electronic Health Record Data

AML - 784

Real-World Treatment Patterns and Outcomes With Olutasidenib After Venetoclax in IDH1-Mutated Acute Myeloid Leukemia Using Electronic Health Record Data

Yasmin Abaza

Poster Presenter: Yasmin Abaza

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.